FDA quick to reject drugs as it gets more cautious

Is the FDA getting gun-shy? The agency has rejected so many drugs this year--and slapped warnings on so many others--that industry observers suspect the agency of a self-preserving caution. It's approved only 61 percent of drug applications so far this year, compared with 73 percent during the same period of 2006, according to BioMed Tracker. New molecular entities--drugs based on totally new chemical compounds--have perhaps fared worst. Only seven have been given the FDA go-ahead this year, compared with an average of 12 during the same seven months of every year since 1998.

None of this is news to battle-scarred drug companies, from Big Pharma on down. But the FDA says it hasn't made any systematic changes in its drug review process. Some experts say the jury's still out. Besides, with so many drugs getting pulled offstage after the show's already started, pre-opening night jitters might not be an excess of caution, but an increase in common sense.

- read the article from The Baltimore Sun

Related Articles:
Industry exec says FDA approval process too strict. Report
Poll finds problems at the FDA. Report
FDA offers safety reforms to skeptical lawmakers. Report
IOM slams FDA, calls for major reforms. Report

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.